Table 2.

Cardiac magnetic resonance imaging (CMR) findings (n (%), unless otherwise indicated).

CMR findings
	Post-COVID-19 (n = 57)	Controls (n = 20)	p
LVEF, %	61 ± 10	63 ± 4	0.68
LVEDV (index), mL/m2	76 ± 17	74 ± 12	0.75
LVESV (index), mL/m2	30 ± 9	27 ± 6	0.83
RVEF, %	60 ± 9	62 ± 6	0.84
RVEDV (index), mL/m2	74 ± 18	75 ± 14	0.67
RVESV (index), mL/m2	30 ± 9	29 ± 8	0.83
Abnormal STIR Myocardial Pericardial	6 (10.5%) 4 (7%) 2 (3.5%)
Native T1, ms <8 weeks (n = 7) ≥8 weeks (n = 50)	996.4 ± 43.9 995 ± 88.3 996.5 ± 38.4	981.5 ± 21.2	0.34
ECV, % Abnormal, % <8 weeks, % (n = 7) ≥8 weeks, % (n = 50)	26.6 ± 3.1 11 (19.3%) 28.3 ± 6 26.5 ± 2.75	–
T2 mapping, ms <8 weeks (n = 7) ≥8 weeks (n = 50)	50.9 ± 4.3 55 ± 12.6 50.51 ± 2.8	48 ± 1.9	<0.01
LGE Non-ischaemic Ischaemic Pericardial	15 (26.3%) 11 (19.3%) 2 (3.5%) 2 (3.5%)
FT-CS <8 weeks (n = 7) ≥8 weeks (n = 50)	18.6 ± 3.3% 15.6 ± 2.2% 18.9 ± 2.6%.	19.2 ± 2.1%	0.52
FT-RS <8 weeks (n = 7) ≥8 weeks (n = 50)	32.3 ± 8.1% 24.9 ± 5.8% 33.5 ± 7.2%	33.6 ± 7.1%	0.90

Abbreviations: ECV, extracellular volume; FT, feature tracking; FT-CS, FT circumferential strain; FT-RS, FT radial strain; LGE, late gadolinium enhancement; LV, left ventricle; LVEDV, LV end-diastolic volume; LVEF, LV ejection fraction; LVESV, LV end-systolic volume; RV, right ventricle; RVEDV, end-diastolic volume; RVEF, RV ejection fraction; RVESV, RV end-systolic volume; STIR, short tau inversion recovery.